Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism

Brain Research Bulletin

Volumn 43, Issue 1, 1997, Pages 93-95

  Domino, Edward F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Addition; Antagonism; Circling behavior; Combination therapy; Dopamine D1 agonists; Dopamine D2 agonists; Monkeys; MPTP induced hemiparkinsonism; N 0923; Potentiation; SKF 82958; Synergism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ROTIGOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; MACACA NEMESTRINA; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 0030980749     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(96)00346-2     Document Type: Article

References (19)

1. 2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys. Jpn. J. Pharmacol. 67:1995;117-124.
2. 2 receptor agonist is efficacious in rat and monkey models of Parkinson's disease. Movement Disord. 9:1994;147-154.
3. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
4. Civelli O. Molecular biology of the dopamine receptor subtypes. Bloom F. E., Kupfer D. J. Psychopharmacology: The fourth generation of progress. 1995;155-161 Raven Press Ltd, New York.
5. 11C]tetrabenazine. Synapse. 14:1993;128-131.
6. 2 agonists in the MPTP monkey model of Parkinson's disease. Program and abstracts, official satellite symposium of the 15th international Society for Neurochemistry meeting on neuromodulators and brain dysfunction, Tokyo, Japan, June 27-28, 1995.
7. 2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 264:1993;221-225.
8. 2 receptors in MPTP induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 265:1387-1391; 1993.
9. 2 receptors in MPTP induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 265:1387-1391; 1993. [Erratum: J. Pharmacol. Exp. Ther. 267:566;1993].
10. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
11. Langston J. W., Ballard P., Tetrud J. W., Irwine I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;279-280.
12. Mansour A., Watson S. J. Jr. Dopamine receptor expression in the central nervous system. Bloom F. E., Kupfer D. J. Psychopharmacology: The fourth generation of progress. 1995;207-219 Raven Press Ltd, New York.
13. 1 dopamine receptor. Neuropharmacology. 28:1995;401-405.
14. Parker W. B., Cheng Y.-C. Disruption of energy metabolism and mitochondrial function. B. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chang L. W., Slikker W. Jr. Neurotoxicology, approaches and methods. 1995;487-488 Academic Press, San Diego.
15. 1 receptor agonists in Parkinson's disease. Koller W. C., Paulson G. Therapy of Parkinson's Disease. 1990;333-344 Marcel Dekker, New York.
16. Roth R. H., Elsworth J. D. Biochemical pharmacology of midbrain dopamine neurons. Bloom F. E., Kupfer D. J. Psychopharmacology: The fourth generation of progress. 1995;227-243 Raven Press Ltd, New York.
17. 2 receptor agonists on motor behavior of MPTP-lesioned monkeys. A preclinical model of Parkinson's disease. Thesis, Department of Experimental Neurology. Vrije Universiteit, Amsterdam, The Netherlands, 1994.
18. 1 agonist, SKF 81,297, stimulates motor behaviour of MPTP lesioned monkeys. Eur. J. Pharmacol. 235:1993;143-147.
19. Zigmond M. J., Stricker E. M. Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications. Int. Rev. Neurobiol. 31:1989;1-79.